Tetraphase Pharmaceuticals

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant (MDR) infections. Since the company’s inception in 2006, Tetraphase has developed an antibiotics platform that offers the potential to dramatically improve the treatment of both broad spectrum and MDR bacterial infections.

NASDAQ: TTPH
Pipeline   Partnerships


We recently completed a successful Phase 2 clinical trial with Tetraphase’s lead product candidate, eravacycline. Eravacycline is being developed as a broad spectrum intravenous and oral antibiotic for treatment of MDR infections. Read more about the company’s advancing clinical pipeline. More >>


With its innovative antibiotics platform, Tetraphase offers significant value for leading pharmaceutical companies. If you are interested in partnering with Tetraphase... More >>




 

      Legal Notes / Privacy © 2013 Tetraphase Pharmaceuticals  

Tetraphase's lead candidates have the potential to treat a broad range of serious bacterial infections. This provides a tremendous opportunity to address the global health crisis caused by the increasing number of infections resistant to currently used antibiotics.

The Tetraphase proprietary drug engine has produced more than 2,600 proprietary compounds with novel molecular structures, reinvigorating one of the best known, safest and most efficacious classes of antibiotics ever discovered.

In just six years, Tetraphase has developed a strong pipeline with a broad spectrum antibiotic lead candidate advancing to Phase 3 clinical trials and several additional candidates in preclinical development.